Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

5 terminated/withdrawn out of 25 trials

Success Rate

78.3%

-8.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

22%

4 of 18 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2
13(52.0%)
Phase 1
12(48.0%)
25Total
Phase 2(13)
Phase 1(12)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT06017609Phase 2Active Not Recruiting

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

Role: lead

NCT07247266Phase 1Recruiting

Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)

Role: lead

NCT04465877Phase 1Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Role: lead

NCT03832738Phase 2Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Role: lead

NCT03358290Phase 2Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

Role: lead

NCT02919475Phase 2Completed

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

Role: lead

NCT03789643Phase 2Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension

Role: lead

NCT03018509Phase 1Completed

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Role: lead

NCT02805244Phase 1Completed

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Role: lead

NCT02581124Phase 1Completed

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Role: lead

NCT02120976Phase 1Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Role: lead

NCT02106585Phase 1Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Role: lead

NCT01971164Phase 1Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Role: lead

NCT01978587Phase 1Completed

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Role: lead

NCT01699737Phase 2Completed

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

Role: lead

NCT00997152Phase 2Terminated

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

Role: lead

NCT00929539Phase 2Completed

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Role: lead

NCT00749788Phase 2Completed

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Role: lead

NCT00748852Phase 2Completed

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Role: lead

NCT01475981Phase 1Completed

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Role: lead